Q2 FY2026 · ended Jun 30, 2026 · Revenue $68,757, -59.1% YoY · Filed Aug 13, 2026
Mangoceuticals, Inc. (MGRX) files with the SEC under industry code 8090, Services-Misc Health & Allied Services, NEC. In Q2 of fiscal 2026, the quarter ended Jun 30, 2026, it reported revenue of $68,757 and a net loss of $1.3 million. As of Jun 30, 2026 it held $228,688 in cash and investments and $279,207 in total debt.
Revenue
$68,757
-59.1% vs year-ago quarter
Net income
$-1.31M
+75.8% vs year-ago quarter
Operating cash flow
$-260,506
+79.3% vs year-ago quarter
Free cash flow
—
EPS
$-0.09
+84.2% vs year-ago quarter
Dividend per share
None
Shares outstanding
21.57M
+104.7% vs year-ago quarter
Net cash
$-50,519
Q2 FY2026
Operating margin
-3829.0%
TTM
Company profile
- Industry
- Services-Misc Health & Allied Services, NEC (SIC 8090)
- Listed as
- MGRX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- TX
- Headquarters
- Dallas, TX
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1938046
- Former names
- MANGOCEUTICALS, INC. (until Oct 9, 2026)
Other Services-Misc Health & Allied Services, NEC companies
- Fresenius Medical Care AG FMS
- Davita Inc. DVA
- Sotera Health Co SHC
- Progyny, Inc. PGNY
- agilon health, inc. AGL
- Charming Medical Ltd MCTA
- Viemed Healthcare, Inc. VMD
- Park Dental Partners, Inc. PARK
All 15 Services-Misc Health & Allied Services, NEC companies
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $68,757 | $67,864 | $94,360 | $84,246 | $168,109 |
| Operating income | -$1.0M | -$3.1M | -$367,739 | -$7.5M | -$5.3M |
| Net income | -$1.3M | -$3.4M | -$2.8M | -$7.6M | -$5.4M |
| Diluted EPS | -$0.09 | -$0.22 | -$0.22 | -$0.69 | -$0.57 |
| Operating cash flow | -$260,506 | -$1.3M | -$1.1M | -$1.2M | -$1.3M |
| Total assets | $14.2M | $14.4M | $16.1M | $16.5M | $20.8M |
| Total liabilities | $1.6M | $974,571 | $890,568 | $804,275 | $1.6M |
| Stockholders' equity | $12.5M | $13.5M | $15.2M | $15.7M | $19.2M |
| Cash and investments | $228,688 | $174,562 | $1.5M | $481,281 | $101,019 |
| Total debt | $279,207 | $294,023 | $307,823 | $294,023 | $30,117 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Material agreement
|
Oct 9, 2026 | Oct 8, 2026 |
| 8-K |
Current report
Material agreement, Acquisition or sale of assets, Unregistered share sale, Regulation FD disclosure
|
Oct 1, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Agreement ended
|
Aug 21, 2026 | Aug 19, 2026 |
| 10-Q | Quarterly report | Aug 13, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Other events
|
Aug 4, 2026 | Aug 4, 2026 |
| 8-K |
Current report
Material agreement, Officer or director change, Bylaw or fiscal year change, Regulation FD disclosure
|
Jul 30, 2026 | Jul 28, 2026 |
All 240 Mangoceuticals, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.